公开(公告)号：US20220227773A1

公开(公告)日：2022-07-21

申请号：US17615300

申请日：2020-05-29

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  TOPHARMAN SHANGHAI CO., LTD. ,  LIAN V NANTONG CO., LTD.

发明人： Jingshan SHEN ,  Yang HE ,  Chunhui WU ,  Feipu YANG ,  Zhen WANG ,  Junchi ZHANG ,  Fuqiang ZHU ,  Hongjian QIN

IPC分类号： C07D487/04 ,  C07D409/04 ,  C07D405/04 ,  C07D209/52

摘要： The present invention relates to a fused ring compound represented by general formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition and use thereof. The compound provided in the present invention is useful for treating, preventing and/or controlling various nervous system disorders. The compound provided in the present invention modulates one or more monoamine transporters, inhibits the reuptake of endogenous monoamines such as dopamine, 5-hydroxytryptamine, and norepinephrine (e.g., from the synaptic cleft), and/or modulates the 5-HT3 receptor.

公开(公告)号：US20240309012A1

公开(公告)日：2024-09-19

申请号：US18009981

申请日：2021-01-11

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Wuhan Institute of Virology, Chinese Academy of Science

发明人： Jingshan SHEN ,  Zhaobing GAO ,  Gengfu XIAO ,  Jia LI ,  Feipu YANG ,  Leike ZHANG ,  Bingqing XIA ,  Xiangrui JIANG ,  Yang HE ,  Hualiang JIANG

IPC分类号： C07D491/18 ,  A61K31/4748 ,  A61P31/14 ,  C07D491/22 ,  C07D498/22 ,  C07D519/00

CPC分类号： C07D491/18 ,  A61K31/4748 ,  A61P31/14 ,  C07D491/22 ,  C07D498/22 ,  C07D519/00

摘要： Provided are an isoquinoline compound represented by formula (I), a pharmaceutically acceptable salt thereof, an enantiomer thereof, a diastereomer, a racemate, a crystalline hydrate, and a solvate, as well as an application of a composition thereof in fighting a virus. R1, R2, R3, and R4 are as defined in the description. Further provided are a preparation method for the compound and uses thereof for preparing an inhibitor that inhibits a virus and/or a drug for prophylaxis and/or treatment of an illness related to a respiratory tract infection, pneumonia, etc. caused by a virus.

公开(公告)号：US20170158680A1

公开(公告)日：2017-06-08

申请号：US15124264

申请日：2015-03-09

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. ,  TOPHARMAN SHANDONG CO., LTD.

发明人： Hualiang JIANG ,  Zhen WANG ,  Jianfeng LI ,  Rongxia ZHANG ,  Yang HE ,  Yongjian LIU ,  Minghao BI ,  Zheng LIU ,  Guanghui TIAN ,  Weiming CHEN ,  Feipu YANG ,  Chunhui WU ,  Yu WANG ,  Xiangrui JIANG ,  Jingjing YIN ,  Guan WANG ,  Jingshan SHEN

IPC分类号： C07D409/12 ,  C07D495/04 ,  C07D471/04

CPC分类号： C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D495/04 ,  C07D519/00

摘要： The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.